%PDF-1.4
%
116 0 obj
<>
endobj
113 0 obj
<>
endobj
275 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-10-07T18:10:54Z
2024-03-18T22:23:24-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-18T22:23:24-07:00
application/pdf
Heather
2003-568.nov
uuid:57f15845-1dd2-11b2-0a00-560827bd3700
uuid:57f15847-1dd2-11b2-0a00-5b0000000000
endstream
endobj
102 0 obj
<>
endobj
103 0 obj
<>
endobj
117 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 80 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 82 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 84 0 R/Type/Page>>
endobj
15 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI]/XObject<>>>/Rotate 0/Thumb 86 0 R/Type/Page>>
endobj
21 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 88 0 R/Type/Page>>
endobj
32 0 obj
<>/Font<>/ProcSet[/PDF/Text/ImageB]/XObject<>>>/Rotate 0/Thumb 90 0 R/Type/Page>>
endobj
39 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 92 0 R/Type/Page>>
endobj
66 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageC/ImageI]/XObject<>>>/Rotate 0/Thumb 94 0 R/Type/Page>>
endobj
70 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 96 0 R/Type/Page>>
endobj
313 0 obj
[318 0 R]
endobj
314 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6229 0.7822 -0.7822 0.6229 12.739 54.1879 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
53.964 76.5 m
558.972 76.5 l
S
0 0 0 0 k
52.822 69.665 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
8 0 0 8 53.8216 56.7343 Tm
(2114)Tj
ET
0 0 0 0 k
356 69.665 203 -15.665 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 420.9531 56.7343 Tm
[(The Journal of Rheumatology 2004; 31:1)74 (1)]TJ
ET
0 0 0 0 k
/GS0 gs
102.75 82.25 407.5 -10.833 re
f*
0.5 w
/GS1 gs
102.75 82.25 407.5 -10.833 re
S
BT
0 0 0 1 k
/T1_2 1 Tf
8 0 0 8 74.932 736.0293 Tm
[(colorectal carcinomas with microsatellite instability)65 (.)]TJ
0 -1.25 TD
(Gastroenterology 2001;121:1275-80.)Tj
-2.175 -1.25 Td
[(19.)-875 (Thorstensen L, Holm R, Lothe RA, et al. )18 (WNT)92 (-inducible signaling)]TJ
2.175 -1.25 Td
[(pathway protein 3, )18 (WISP-3, is mutated in microsatellite unstable)]TJ
T*
(gastrointestinal carcinomas but not in endometrial carcinomas.)Tj
T*
(Gastroenterology 2003;124:270-1.)Tj
-2.175 -1.25 Td
[(20.)-875 (Hurvitz JR, Suwairi )18 (WM, )18 (V)111 (an Hul )18 (W)92 (, et al. Mutations in the CCN)]TJ
2.175 -1.25 Td
[(gene family member )18 (WISP3 cause progressive pseudorheumatoid)]TJ
T*
(dysplasia. Nat Genet 1999;23:94-8.)Tj
-2.175 -1.25 Td
[(21.)-875 (Arnett FC, Edworthy SM, Bloch DA, et al. )18 (The )55 (American)]TJ
2.175 -1.25 Td
[(Rheumatism )55 (Association 1987 revised criteria for the classification)]TJ
T*
[(of rheumatoid arthritis. )55 (Arthritis Rheum 1988;31:315-24.)]TJ
-2.175 -1.25 Td
[(22.)-875 (Alvaro-Gracia JM, Zvaifler NJ, Brown CB, Kaushansky K,)]TJ
2.175 -1.25 Td
[(Firestein GS. Cytokines in chronic inflammatory arthritis. )18 (VI.)]TJ
T*
(Analysis of the synovial cells involved in granulocyte-macrophage)Tj
T*
(colony-stimulating factor production and gene expression in)Tj
T*
(rheumatoid arthritis and its regulation by IL-1 and tumor necrosis)Tj
T*
[(factor)20 (-alpha. J Immunol 1991;146:3365-71.)]TJ
-2.175 -1.25 Td
[(23.)-875 (Elices MJ, )18 (T)70 (sai )18 (V)129 (, Strahl D, et al. Expression and functional )]TJ
2.175 -1.25 Td
(significance of alternatively spliced CS1 fibronectin in rheumatoid)Tj
T*
(arthritis microvasculature. J Clin Invest 1994;93:405-16.)Tj
-2.175 -1.25 Td
[(24.)-875 (Boyle DL, Rosengren S, Bugbee )18 (W)92 (, Kavanaugh )55 (A, Firestein GS.)]TJ
2.175 -1.25 Td
(Quantitative biomarker analysis of synovial gene expression by)Tj
T*
[(real-time PCR. )55 (Arthritis Res )18 (Ther 2003;5:R352-60.)]TJ
-2.175 -1.25 Td
[(25.)-875 (T)70 (anaka S, )55 (Akiyoshi )18 (T)74 (, Mori M, )18 (W)80 (ands JR, Sugimachi K. )55 (A)-220 (novel)]TJ
2.175 -1.25 Td
(frizzled gene identified in human esophageal carcinoma mediates)Tj
T*
[(APC/beta-catenin signals. Proc Natl )55 (Acad Sci USA)]TJ
0 Tc 0 Tw T*
(1998;95:10164-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(26.)-875 (Babic )55 (AM, Kireeva ML, Kolesnikova )18 (TV)129 (, Lau LF)80 (. CYR61, a )]TJ
2.175 -1.25 Td
[(product of a growth factor)20 (-inducible immediate early gene, )]TJ
T*
[(promotes angiogenesis and tumor growth. Proc Natl )55 (Acad Sci USA)]TJ
0 Tc 0 Tw T*
(1998;95:6355-60.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(27.)-875 (Hashimoto )37 (Y)129 (, Shindo-Okada N, )18 (T)70 (ani M, et al. Expression of the)]TJ
2.175 -1.25 Td
(Elm1 gene, a novel gene of the CCN \(connective tissue growth )Tj
T*
[(factor)40 (, Cyr61/Cef10, and neuroblastoma overexpressed gene\) )]TJ
T*
[(family)65 (, suppresses in vivo tumor growth and metastasis of K-1735)]TJ
T*
(murine melanoma cells. J Exp Med 1998;187:289-96.)Tj
-2.175 -1.25 Td
[(28.)-875 (Kireeva ML, Mo FE, )37 (Y)100 (ang GP)111 (, Lau LF)80 (. Cyr61, a product of a)]TJ
2.175 -1.25 Td
[(growth factor)20 (-inducible immediate-early gene, promotes cell )]TJ
T*
(proliferation, migration, and adhesion. Mol Cell Biol)Tj
0 Tc 0 Tw T*
(1996;16:1326-34.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(29.)-875 (O\325Brien )18 (TP)111 (, Lau LF)80 (. Expression of the growth factor)20 (-inducible)]TJ
2.175 -1.25 Td
(immediate early gene cyr61 correlates with chondrogenesis during)Tj
T*
[(mouse embryonic development. Cell Growth Dif)18 (fer 1992;3:645-54.)]TJ
30.696 53.75 Td
[(30.)-875 (W)80 (ong M, Kireeva ML, Kolesnikova )18 (TV)129 (, Lau LF)80 (. Cyr61, product of)]TJ
2.175 -1.25 Td
[(a growth factor)20 (-inducible immediate-early gene, regulates )]TJ
T*
(chondrogenesis in mouse limb bud mesenchymal cells. Dev Biol)Tj
0 Tc 0 Tw T*
(1997;192:492-508.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(31.)-875 (Xu L, Corcoran RB, )18 (W)80 (elsh JW)92 (, Pennica D, Levine )55 (AJ. )18 (WISP-1 is a)]TJ
2.175 -1.25 Td
(Wnt-1- and beta-catenin-responsive oncogene. Genes Dev)Tj
0 Tc 0 Tw T*
(2000;14:585-95.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(32.)-875 (Kleer CG, Zhang )37 (Y)129 (, Pan Q, et al. )18 (WISP3 is a novel tumor )]TJ
2.175 -1.25 Td
[(suppressor gene of inflammatory breast cancer)55 (. Oncogene)]TJ
0 Tc 0 Tw T*
(2002;21:3172-80.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(33.)-875 (Saxena N, Banerjee S, Sengupta K, Zoubine MN, Banerjee SK.)]TJ
2.175 -1.25 Td
[(Dif)18 (ferential expression of )18 (WISP-1 and )18 (WISP-2 genes in normal)]TJ
T*
(and transformed human breast cell lines. Mol Cell Biochem)Tj
0 Tc 0 Tw T*
(2001;228:99-104.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(34.)-875 (Zoubine MN, Banerjee S, Saxena NK, Campbell DR, Banerjee SK.)]TJ
2.175 -1.25 Td
[(WISP-2: a serum-inducible gene dif)18 (ferentially expressed in human)]TJ
T*
(normal breast epithelial cells and in MCF-7 breast tumor cells.)Tj
0 Tc T*
(Biochem Biophys Res Commun 2001;282:421-5.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(35.)-875 (Xie D, Nakachi K, )18 (W)80 (ang H, Elashof)18 (f R, Koef)18 (fler HP)111 (. Elevated )]TJ
2.175 -1.25 Td
[(levels of connective tissue growth factor)40 (, )18 (WISP-1, and CYR61 in)]TJ
T*
(primary breast cancers associated with more advanced features.)Tj
T*
(Cancer Res 2001;61:8917-23.)Tj
-2.175 -1.25 Td
[(36.)-875 (T)70 (anaka S, Sugimachi K, Saeki H, et al. )55 (A)-220 (novel variant of )18 (WISP1)]TJ
2.175 -1.25 Td
[(lacking a )18 (V)129 (on )18 (W)40 (illebrand type C module overexpressed in )]TJ
T*
(scirrhous gastric carcinoma. Oncogene 2001;20:5525-32.)Tj
-2.175 -1.25 Td
[(37.)-875 (Sen M, Cheng )37 (YH, Goldring MB, Lotz MK, Carson DA. )]TJ
2.175 -1.25 Td
(WISP3-dependent regulation of type II collagen and aggrecan )Tj
T*
[(production in chondrocytes. )55 (Arthritis Rheum 2004;50:488-9.)]TJ
-2.175 -1.25 Td
[(38.)-875 (Hadjiar)18 (gyrou M, )55 (Ahrens )18 (W)92 (, Rubin CT)74 (. )18 (T)70 (emporal expression of the)]TJ
2.175 -1.25 Td
(chondrogenic and angiogenic growth factor CYR61 during fracture)Tj
T*
[(repair)55 (. J Bone Miner Res 2000;15:1014-23.)]TJ
-2.175 -1.25 Td
[(39.)-875 (Chevalier G, )37 (Y)100 (eger H, Martinerie C, et al. novH: dif)18 (ferential)]TJ
2.175 -1.25 Td
[(expression in developing kidney and )18 (W)40 (ilm\325)55 (s tumors. )55 (Am J Pathol)]TJ
0 Tc 0 Tw T*
(1998;152:1563-75.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(40.)-875 (van Golen KL, Davies S, )18 (W)40 (u ZF)80 (, et al. )55 (A)-220 (novel putative )]TJ
2.175 -1.25 Td
[(low-af)18 (finity insulin-like growth factor)20 (-binding protein, LIBC \(lost)]TJ
T*
(in inflammatory breast cancer\), and RhoC GTPase correlate with)Tj
T*
(the inflammatory breast cancer phenotype. Clin Cancer Res)Tj
0 Tc 0 Tw T*
[(1999;5:251)37 (1-9.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(41.)-875 (Han Z, Boyle DL, Shi )37 (Y)129 (, Green DR, Firestein GS. Dominant )]TJ
2.175 -1.25 Td
[(negative p53 mutations in rheumatoid arthritis. )55 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1999;42:1088-92.)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
ET
/GS2 gs
BT
/T1_3 8 Tf
112.368 73 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 18, 2024 from )Tj
ET
endstream
endobj
96 0 obj
<>stream
8;Z\7Mf-Ed#iu#8OPcHE_qj"^H*lf_9kI;R`0eSb5j,lBIu1^=qdSs1i]1<`:0qSf
MsX0@Q_lleCk#'0c"45e?)t=n;e^6`#G"UO1,5C\IS*cLO^M_!W7b&A4(Gd5BidI:
1Y`.OQ1Z3qg/WYVY9qn7@P%Z)CL`Bk;LDMq52Q>tP/`KC<@PpFW#_\^oK3,P6V;!%
l!X#c-R-CfJgQ`-(mCjZf66qL8GC#Ei-]U1VJ5E-
p+F689?t*f+E3'0f3aaF6E&P/KBf>ecfTbXRFt>rUV`1&V(iIE$-4HCWDk5N@]:Nm
7e>N+SI>F^/ThFOOP,>7i*X/i^9\HDb[+Y,P?U$jl&gkW2dX
$od'[&NqTlFBra$"&43Ldl8iY?=r3,7gfRKTbFc(\:tkqUhFAK4gK?MW#ug1;i[Jk
kWY4=b`Vi,3/\`5]BKJQ'`\Z[]UiLt7J>jT()\ZVX\1+0ZtNoC46Za*kMudCN6ii[
EfP@*7Uf-$Fc%#NJ@Du>f3gG18YZUNHm8(%Hk3Q9C;N:I<+o+).ZS
A.IsFcRjq>Z=gO`^7Qu0joS,u$.cHjb/>m0f20N2TKOXWH,Vm;g.Uio=:.^a3ES%q
.q-;@.(!V)OK"MSh1$rXRm5QdIg2M^
>dEE:56CoM]Q
endstream
endobj
100 0 obj
[/Indexed/DeviceRGB 255 99 0 R]
endobj
99 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
179 0 obj
<>
endobj
123 0 obj
<>
endobj
128 0 obj
<>
endobj
160 0 obj
<>
endobj
281 0 obj
<>
endobj
129 0 obj
<>
endobj
152 0 obj
<>stream
H|T PWQagB05(%#rCTQNT9gq"hpU3h mL*U~{ߏcFbw
^n[ãyUrKXkeJ&D1+5@.HsWV֯քufpZr_8.(,8::wt\J;,N6'N|ْvG\کmI)5UZ+SΗܢdYBy?UeqPE<6R%[T%222t*V4;5p7.;o0c2V`J+LaEvJ1|80#k/#L\i=%̈ *xqO|ʛŋ])Sb95ejϴ=6Y`g2jp0Q8`6tMG)?_وv+fxOmigY--XVAV
]X3Ak]gZ& Yt9
T|1[+30 NWV#z'aBup'nF,v*#rsF&2>"F*ހUD~,dzn0R.\Âr[wd+*P[liqVinr6BH2 %bݩβ]t{kxETuJm$DnS~ okV*ԠUbkh $f2
#Hd٢4
Ibw$>%Z*
>{&IN&aM%Z\hd'BgLPUI yAŁ%U*S
;uw)DM8((InH+OYJ;Q~=#Z#dh5dImSs:AZPvoJ CZ]zICFm֪j,H(F]S/ʐ
GdGKd ]#laՇeZwOQEG
F.J*tAa<{K _If\W'~$P\ _uh6@<ŁK)7r[r+#m(HYF\"2G